AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02511301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyrcadia CBR™ device placement for abnormality screening
Description: Cyrcadia CBR™ device, including adhesive patches on both breasts connected to a small recorder, is placed on the study subject for 2 to 24 hours. After the test period, the CBR™ will be removed and the data will be downloaded to a central site for analysis. There are no interventions after the CBR™ is removed from the Study Subject.
Study NCT02670369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting time prompt
Description: Participants will receive a device that prompts them to take breaks from sitting approximately every 15-20 minutes.
Study NCT03082729 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Apremilast
Description: Apremilast (brand name Otezla) is a medication for the treatment of certain types of psoriasis and psoriatic arthritis.
Study NCT01721538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight reduction program
Study NCT01721538 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lecture on healthy nutrition
Study NCT02672176 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Usual Care
Description: This program is a well-established program within the UC Davis Health System, providing care coordination to individuals with chronic conditions. Patients can self-refer or are referred by their providers for this service. The role of the care coordinator is to assess needs of the patient and coordinate healthcare referrals and appointments for the patient, facilitate communication among members of the healthcare team, identify health goals in collaboration with the patient and assist them in meeting those goals if requested by the patient. Contact is variable and conducted on a case by case basis.
Study NCT02672176 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: P2E2T2 Program
Description: The P2E2T2 intervention group will receive Nurse Health Coaching using MI, an approach designed to elicit and support behavioral changes and improve self-efficacy (18-21). Nurses delivering the intervention will have completed the Health Science Institutes Registered Health Coach (RHC) training program (www.healthsciences.org). The intervention protocol is as follows:
Study NCT01162044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer game
Description: Playing with specially designed computer game while in emergency room
Study NCT04321772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Resistance Training
Description: Subjects trained one leg with HIIRT
Study NCT04321772 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Resistance Training
Description: Subjects trained the other leg with HIIRT
Study NCT02696395 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DePuy Tri-Lock® femoral stem + Deltamotion® acetabular component
Study NCT02696395 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DePuy Corail® femoral stem + Deltamotion® acetabular component
Study NCT03117634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treat and Extend with Aflibercept 2mg
Description: Drug treatment regime which allows extension of treatment interval based on disease activity
Study NCT03117634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fixed Dosing with Aflibercept 2mg
Description: Fixed 8 weekly dosing regime throughout the study duration
Study NCT04052607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LH Suppression
Description: Stimulation protocols
Study NCT04052607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LH Suppression
Description: Stimulation protocols
Study NCT03541291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMART-SYNC LM03
Description: Doppler ultrasound cardiac gating device for fetal MRI application
Study NCT02100839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEM-28
Description: Solution for injection
Study NCT02100839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% saline for injection
Study NCT03442725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: Oral administration of 1 tablet of Xermelo® containing telotristat etiprate equivalent to 250 mg telotristat ethyl.
Study NCT03442725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telotristat etiprate
Description: Oral administration of 1 tablet of Xermelo® containing telotristat etiprate equivalent to 250 mg telotristat ethyl.
Study NCT03440619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00013
Description: Investigational pulse oximeter device that will be placed on the subject's finger. This will be used as a spotcheck device
Study NCT04389528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromodulation by tDCS
Description: The tDCS is a device for modulating cortical excitability. It consists of passing a low intensity direct electrical current over the scalp via two electrodes: an anode and a cathode soaked in a saline solution. Although there is a short-circuit effect through the scalp, a significant amount of electrical current enters the brain and changes the transmembrane potential.
Study NCT04389528 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neuromodulation by tDCS
Description: The tDCS is a device for modulating cortical excitability. It consists of passing a low intensity direct electrical current over the scalp via two electrodes: an anode and a cathode soaked in a saline solution. Although there is a short-circuit effect through the scalp, a significant amount of electrical current enters the brain and changes the transmembrane potential.
Study NCT00431093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tibolone
Description: uncoded tablets, at a dose of 2.5 mg per tablet; Subjects were to take 1 Livialâ tablet and 1 -matched Activelleâ placebo tablet, orally, once a day (preferably at the same time).
Study NCT00431093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose estradiol/noresterone
Description: Activelleâ, estradiol (E2) 1 mg and norethisterone acetate (NETA) 0.5 mg per tablet, was supplied as uncoded tablets.~Subjects were to take 1 Activelleâ tablet and 1 Livialâ-matched placebo tablet, orally, once a day (preferably at the same time).
Study NCT02490774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1007626
Description: Intrauterine device with 4 different in vitro release rates (low, low to medium, medium, high)
Study NCT02490774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Jaydess
Description: Jaydess: Intrauterine device with a nominal in vitro release of 12 µg levonorgestrel/day
Study NCT02490774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirena
Description: Mirena: Intrauterine device with a nominal in vitro release of 20 µg levonorgestrel/day
Study NCT00090896 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody
Study NCT01557478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: 20 mg melatonin gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
Study NCT01557478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: match placebo
Description: placebo gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
Study NCT03569098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Investigators will inject the reconstituted solution into foot muscles.
Study NCT03569098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Investigators will inject the reconstituted solution into foot muscles.
Study NCT01416545 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational program in cardiovascular prevention
Description: a weekly educational program in cardiovascular prevention with a multidisciplinary heath team during the year 2010. This intervention tried to teach to these children, in different manners appropriate for their age, concepts of healthy nutrition, avoidance of tobacco and physical activity. Both at the inclusion in the study and one year later we collect data of parents and their children of the two groups, in a single weekend, including nutritional and exercise survey, measures of weigh, height, waist circumference, arterial blood pressure, and laboratorial exams.
Study NCT01416545 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle counseling
Description: The control group received written educational material directed for their parents and related to healthy lifestyle (nutrition, exercise and smoke quitting).
Study NCT00689962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Linvatec 4.5 mm Smart Screw
Description: Linvatec 4.5 mm Smart Screw to surgically fix the foot's Lisfranc ligaments
Study NCT00689962 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synthes 4.0 mm steel screw
Description: Standard steel screw use to surgically fix the foot's Lisfranc ligaments.
Study NCT02892617 — intervention group
Intervention type: OTHER
Intervention: Bacteriological analysis of disc
Study NCT00616551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C2L-OCT-01 PR, 30 mg
Description: Administered by deep IM injection (gluteus) on days 1 and 42
Study NCT00616551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide acetate prolonged release, 30 mg
Description: Administered by deep IM (gluteus) on Days 1, 28 and 56
Study NCT04009603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Agent
Description: Probiotics are live microorganisms, which when administered in adequate amounts confer a health benefit effects on the host.~Many clinical trials have been done on probiotic which show its use as a single or as an adjuvant drug therapy for various diseases with no or rare side effects. It is now frequently used agent for various diseases.~Apart from this many studies have been published related to effects of probiotics on PCOS, which shows effectiveness of probiotics when used for 8 to 12 weeks with no adverse effects observed by these micro-organisms but none of the study have compare it with standarad drug
Study NCT04009603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin, an insulin sensitizer, is an oral biguanide that is most commonly prescribed for the management of type II diabetes mellitus and various symptoms of PCOS. It is derived from the extract of Galega officinalis.~It remediates hyperglycemia through activation of AMPK which stimulates glucose uptake and its consumption; promote fatty acid oxidation along with suppression of hepatic glucose production. It is also involved in increase GLUT4 translocation in the muscle and fat leading to decrease hepatic lipid synthesis. Moreover, It is also reported that it decreases gut absorption of glucose by increasing the glucagon-like peptide-1 (GLP-1) in this way, it reduces the insulin requirement too.All of these actions of metformin decrease insulin resistance and thus improve the state of hyperinsulinemia associated with diabetes and PCOS
Study NCT04009603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin, an insulin sensitizer, is an oral biguanide that is most commonly prescribed for the management of type II diabetes mellitus and various symptoms of PCOS. It is derived from the extract of Galega officinalis.~It remediates hyperglycemia through activation of AMPK which stimulates glucose uptake and its consumption; promote fatty acid oxidation along with suppression of hepatic glucose production. It is also involved in increase GLUT4 translocation in the muscle and fat leading to decrease hepatic lipid synthesis. Moreover, It is also reported that it decreases gut absorption of glucose by increasing the glucagon-like peptide-1 (GLP-1) in this way, it reduces the insulin requirement too.All of these actions of metformin decrease insulin resistance and thus improve the state of hyperinsulinemia associated with diabetes and PCOS
Study NCT04069715 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng extract)
Description: A product made of highly concentrated pharmaceutical grade notoginseng root extract, and containing high potency bioactive components, notoginsenoside, ginsenoside Rb1, Rg1, Rd, Re and Rb2.
Study NCT04069715 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Turmeric 0.4%, Rice Flour 76.6%, Magnesium stearate 23%, capsule shell (gelatin) 61 mg
Study NCT00334789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Given IV
Study NCT00334789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Given orally
Study NCT00334789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT04264780 — intervention group
Intervention type: OTHER
Intervention: Neuropsychological examination
Description: Neuropsychological follow-up examination, including questionaires
Study NCT02262650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Study NCT02262650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Study NCT02262650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study NCT02262650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Study NCT00675987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan
Description: losartan 100 mg tablets 1 tab po QD
Study NCT00675987 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo 1 po QD
Study NCT01795794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Study NCT01450319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m\^2) every 2 weeks until disease progression, death, or consent withdrawal.
Study NCT01613261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-733 and alisertib
Description: TAK-733 will be administered orally once daily (QD) on Days 1 through 14 of the 21-day cycle.~Alisertib will be administered orally twice daily (BID) on Days 1 through 7 of the 21-day cycle.
Study NCT00823134 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ApneaLink Plus
Description: Device used to evaluate for the presence of obstructive, central or mixed apneas
Study NCT02192671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic Resection
Description: Indications for HR are the presence of appropriate residual liver volume determined by volumetric computed tomography.
Study NCT02192671 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation
Study NCT03756415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiMax Zero Total face mask R,
Description: a non-CO2 rebreathing device included directly in the full face mask
Study NCT03756415 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional face mask
Description: a traditional mask without a non-CO2 rebreathing device included directly in the full face mask
Study NCT04575220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12 weeks of bicycle exercise
Description: Subjects will conduct monitored exercise, three sessions per week for 12 weeks.
Study NCT01828970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal-bolus detemir-aspart insulin regimen
Description: After the first CGM was completed during the conventional anti-diabetic treatment, patients received a rapid-acting insulin analogue before each meal (i.e., aspart) and a basal long-acting insulin analogue (i.e., detemir) once or twice daily. The analogues were titrated for optimal glycemic control. After one month of the aspart and detemir regimen, a physician adapted the insulin doses according to the glucose values observed from the second CGM.
Study NCT00498680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil, Vardenafil
Description: Sildenafil 100mg, vardenafil 20mg, combination of both half dosage.
Study NCT00498680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 100mg
Study NCT00498680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vardenafil
Description: 20mg
Study NCT00498680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil & Vardenafil
Description: 50mg \& 10 mg
Study NCT03434210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LAT-treated Community Model
Description: The subjects in experimental group is on 'LAT-treated Community Model'. which means,beside care as usual, subjects will be treated by paliperidone palmitate, Psychiatrists will guide community mental health professinals about the treatment and management. Psychiatrists will give community mental health professinals and patients/ caregiver long acting injection related education information.
Study NCT03434210 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: care as usual
Description: Control group will get usual community care, the treatment is identified by doctors, patients and care-giver as usual.
Study NCT00699777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate
Description: 1 risedronate 150 mg tablet administered orally
Study NCT00699777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: 2 risedronate 75 mg tablets administered as a single oral dose
Study NCT03547024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942 High Dose
Description: Participants will receive high dose of JNJ-55308942 orally once daily.
Study NCT03547024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942 Low Dose
Description: Participants will receive low dose of JNJ-55308942 orally once daily.
Study NCT03547024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel/Ethinyl Estradiol Fixed Dose combination (FDC)
Description: Participants will receive 0.150 milligram (mg) levonorgestrel and 0.030 mg ethinyl estradiol FDC tablet orally.
Study NCT03547024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Cocktail:Midazolam (2mg)/Omeprazole (20mg)/Dextromethorphan (30mg)
Description: Participants will receive single dose of drug cocktail consisting of midazolam (2 mg), dextromethorphan (30mg) and omeprazole (20 mg) orally.
Study NCT02630862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin is a standard and guidelines supported therapy for patients undergoing carotid endoarterectomy as secondary prevention measure of cardiovascular risk
Study NCT02630862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin plus dipyridamole
Description: the combination of aspirin plus dipyridamole is approved to lower the risk of stroke in people who have had a transient ischemic attack or stroke
Study NCT02233218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Study NCT02233218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Study NCT02233218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT01243918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen therapy delivery systems
Description: T-60 (minutes) : clinical examination, blood gas, electrocardiogram; T0 / First oxygen therapy delivery system: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2; T10 : blood gas; Between T0 and T60 (every 10 minutes): clinical examination, measurement of positive and expiratory pressure and FiO2; T60 / Second oxygen therapy delivery system: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2; T70 : blood gas; Between T60 and T120 (every 10 minutes): clinical examination, measurement of positive and expiratory pressure and FiO2; T120: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2
Study NCT04318704 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ifenprodil
Description: Ifenprodil 20 mg TID
Study NCT02981030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Women seeking medical abortion will be offered the option to take mifepristone at home
Study NCT02981030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Women seeking medical abortion will be offered the option to take misoprostol at home. Misoprostol will be administered buccally.
Study NCT01116921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (nCPAP)
Description: nCPAP equipment used in the trial will be the standard hospital equipment used in the NICU.
Study NCT01116921 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal continuous positive airway pressure (nCPAP)
Description: nCPAP equipment used in the trial will be the standard hospital equipment used in the NICU.
Study NCT01116921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA) to deliver surfactant
Description: Laryngeal Mask Airway (LMA Unique-Size 1, The Laryngeal Mask Company Limited, San Diego, CA)